|
Talecris Biotherapeutics Holdings taps into the healing power of blood. The biopharmaceutical company develops protein therapy products (derived from blood plasma) used to treat conditions such as immune deficiency disorders, severe burns, and hemophilia. The plasma proteins help control bleeding and body function, as well as combat infection. Its lead product, Gamunex IGIV, helps in the treatment of immune deficiency conditions and leukemia, and with bone marrow transplant recovery. Its Prolastin product is used to treat emphysema. Talecris Biotherapeutics operates worldwide from offices in North America and Germany. Cerberus Capital Management controls the company.
|
| | | Contact Information | |
Address: |
4101 Research Commons, 79 T.W. Alexander Dr.
Research Triangle Park, NC 27709
| | Phone: | 919-316-6300 | | Fax: | 919-316-6316 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 1374.30 M | | Revenue Growth (1 yr): | 12.80% | | Employees (2008): | 4,763 | | Employee Growth (1 yr): | 10.80% |
|
|
Key People
| | • |
Chairman and CEO:
Lawrence D. (Larry) Stern
| | • |
EVP Operations:
Mary J. Kuhn
| | • |
EVP and CFO:
John M. Hanson
|
|
|
